EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention

Hans Chinomso Chris-Uchendu iD, Gerald Olwit iD, Arnold Atuhaire iD, Isaac Matovu iD, Hope Nakakande Kirumira, Patrick Kambale Sasiita, Leo Odongo iD, Andrew Mutekanga, Jacob Nkwanga

Clinical Pharmacology: Advances and Applications · 2026-06 · Volume 18 · 1-19

DOI: 10.2147/cpaa.s622588 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2026-06. Verfasst von Hans Chinomso Chris-Uchendu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, School of Medicine, Kabale University, Kabale, Uganda. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenacapavir (LEN), a first-in-class HIV-1 capsid inhibitor administered subcutaneously twice yearly, has demonstrated near-perfect efficacy in Phase 3 trials, generating justified enthusiasm for its potential to reconfigure HIV prevention. However, its revolutionary success obscures critical spatiotemporal vulnerabilities. We critically examined the protective envelope of LEN, specifically focusing on the gap between systemic pharmacokinetics (PK) and mucosal distribution, the dynamics of the prolonged PK tail, and the clinical emergence of capsid resistance.

Methods

A systematic narrative synthesis was conducted through April 2026. We integrated screening and data parameters from the PURPOSE and CAPELLA trials alongside advanced PK-PD modeling and structural biology datasets to comprehensively map the spatiotemporal parameters of lenacapavir-based PrEP.

Findings

We characterize the Limitations of Systemic Surrogacy, highlighting that no published empirical data exist characterizing LEN concentrations in human mucosal sanctuary sites; the sole registered tissue distribution trial (Pro00043856) remains unpublished four years post-registration. While modeling baseline assumptions establish a wild-type 95% preventive plasma concentration (EC 95 ) of 5.8 ng/mL, the terminal absorption-limited elimination phase creates a definitive 106– 235 day Mutant Selection Window (MSW) following drug discontinuation. Based on the 58 studies included in the full synthesis, falling sub-therapeutic drug concentrations during this tail phase exert selective pressure that favors high-fitness capsid substitutions (eg, Q67H), lowering the genetic barrier for complex, high-level resistance mutations (eg, N74D). Clinical breakthrough infections observed across the CAPELLA trial (19%) and rare PURPOSE infections (0.07 per 100 person-years) validate this corridor of vulnerability, highlighted by a recorded seroconversion occurring 16 months post-injection.

Conclusion

Optimizing the public health impact of lenacapavir requires transitioning from simple serum-based monitoring toward tissue-informed clinical stewardship. Unlike conventional oral PrEP, twice-yearly lenacapavir involves an extended pharmacological commitment of nearly 12 months, requiring pre-planned clinical protocols for bridging therapy during drug discontinuation. Implementation requires the evaluation of high-sensitivity viral surveillance tools ( LOD ≤ 10 copies/mL) and global access reconfigurations to resolve the economic and licensing barriers separating low-cost generic synthesis from international list prices, protecting the long-term viability of the capsid inhibitor class across all implementation sectors. A flowchart detailing three phases: active prophylaxis, discontinuation and clinical stewardship. Keywords: lenacapavir, HIV pre-exposure prophylaxis, pharmacokinetics, drug resistance, viral, global health equity, capsid inhibitor, area under curve

Schlagwörter

Stichwörter der Autor:innen

HIV pre-exposure prophylaxisarea under curvecapsid inhibitordrug resistanceglobal health equitylenacapavirpharmacokineticsviral

Autor:innen und Institutionen

  • Department of Surgery, School of Medicine, Kabale University, Kabale, Uganda.
  • Department of Internal Medicine, School of Medicine, Kabale University, Kabale, Uganda.
  • Department of Obstetrics and Gynaecology, Kabale University School of Medicine, Kabale, Uganda.
  • Department of Nursing Science, School of Medicine, Kabale University, Kabale, Uganda.
  • Department of Dermatology, Allergology, and Venereology, Kabale University School of Medicine, Kabale, Uganda.

ORCID-Profile: Hans Chinomso Chris-Uchendu, Gerald Olwit, Arnold Atuhaire, Isaac Matovu, Leo Odongo

Zitieren

APA

Chris-Uchendu, H. C., Olwit, G., Atuhaire, A., Matovu, I., Kirumira, H. N., Sasiita, P. K., Odongo, L., Mutekanga, A., & Nkwanga, J. (2026). Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention. Clinical Pharmacology: Advances and Applications, Volume 18, 1-19. https://doi.org/10.2147/cpaa.s622588

Vancouver

Chris-Uchendu HC, Olwit G, Atuhaire A, Matovu I, Kirumira HN, Sasiita PK, et al. Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention. Clinical Pharmacology: Advances and Applications. 2026;Volume 18:1-19. doi:10.2147/cpaa.s622588

BibTeX
@article{ChrisUchendu2026,
  author = {Chris-Uchendu, Hans Chinomso and Olwit, Gerald and Atuhaire, Arnold and Matovu, Isaac and Kirumira, Hope Nakakande and Sasiita, Patrick Kambale and Odongo, Leo and Mutekanga, Andrew and Nkwanga, Jacob},
  title = {Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention},
  journal = {Clinical Pharmacology: Advances and Applications},
  year = {2026},
  volume = {Volume 18},
  pages = {1--19},
  doi = {10.2147/cpaa.s622588}
}
Kostenlos starten →